CNM-Au8市場：市場規模、予測、新たな洞察-2032年

CNM-Au8は、エネルギーの生産と利用を増加させることにより、神経細胞の健康と機能を回復させるために開発された金ナノ結晶の経口懸濁液です。CNM-Au8の触媒活性ナノ結晶は、重要な細胞エネルギー産生反応を促進し、疾患に関連するストレス要因に対する神経細胞とグリアの回復力を高めることで、神経保護と再髄鞘化を可能にします。

CNM-Au8は、パーキンソン病を対象とした第II相臨床試験を完了し、神経変性疾患の治療において有意義な神経機能改善を促すCNM-Au8の可能性を裏付けるデータが得られました。同社は、パーキンソン病患者における疾患の進行を遅らせたり、予防したりするCNM-Au8の効果を調査するため、資本の利用可能性に応じて別の第II相試験を実施する予定です。

今後数年間で、パーキンソン病の市場シナリオは、世界中の広範な調査と医療費の増加により変化します。各社は、病状を治療/改善するための新しいアプローチに焦点を当てた治療法を開発し、課題を評価し、CNM-Au8の優位性に影響を与える可能性のある機会を模索しています。パーキンソン病に対する他の新興製品は、CNM-Au8と厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるパーキンソン病治療薬のCNM-Au8市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 パーキンソン病におけるCNM-Au8の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 CNM-Au8市場評価

• パーキンソン病におけるCNM-Au8の市場展望
• 主要7ヶ国分析
  • 主要7ヶ国のパーキンソン病治療薬CNM-Au8の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: CNM-Au8, Clinical Trial Description, 2023
• Table 2: CNM-Au8, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: CNM-Au8 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: CNM-Au8 Market Size in the US, in USD million (2019-2032)
• Table 7: CNM-Au8 Market Size in Germany, in USD million (2019-2032)
• Table 8: CNM-Au8 Market Size in France, in USD million (2019-2032)
• Table 9: CNM-Au8 Market Size in Italy, in USD million (2019-2032)
• Table 10: CNM-Au8 Market Size in Spain, in USD million (2019-2032)
• Table 11: CNM-Au8 Market Size in the UK, in USD million (2019-2032)
• Table 12: CNM-Au8 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: CNM-Au8 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: CNM-Au8 Market Size in the United States, USD million (2019-2032)
• Figure 3: CNM-Au8 Market Size in Germany, USD million (2019-2032)
• Figure 4: CNM-Au8 Market Size in France, USD million (2019-2032)
• Figure 5: CNM-Au8 Market Size in Italy, USD million (2019-2032)
• Figure 6: CNM-Au8 Market Size in Spain, USD million (2019-2032)
• Figure 7: CNM-Au8 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: CNM-Au8 Market Size in Japan, USD million (2019-2032)

"CNM-Au8 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about CNM-Au8 for Parkinson's disease in the seven major markets. A detailed picture of the CNM-Au8 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the CNM-Au8 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CNM-Au8 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary:

CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy-producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors.

CNM-Au8 has completed a Phase II trial for Parkinson's disease, data supported the potential of CNM-Au8 to drive meaningful neurological functional improvements in the treatment of neurodegenerative disorders. The company is planning to conduct another Phase II trial subject to capital availability to investigate the effects of CNM-Au8 on slowing or preventing disease progression in Parkinson's disease patients.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the CNM-Au8 description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on CNM-Au8 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the CNM-Au8 research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around CNM-Au8.
• The report contains forecasted sales of CNM-Au8 for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for CNM-Au8 in Parkinson's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CNM-Au8 Analytical Perspective by DelveInsight

• In-depth CNM-Au8 Market Assessment

This report provides a detailed market assessment of CNM-Au8 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• CNM-Au8 Clinical Assessment

The report provides the clinical trials information of CNM-Au8 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CNM-Au8 dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to CNM-Au8 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CNM-Au8 in Parkinson's disease.
• Our in-depth analysis of the forecasted sales data of CNM-Au8 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CNM-Au8 in Parkinson's disease.

Key Questions:

• What is the product type, route of administration and mechanism of action of CNM-Au8?
• What is the clinical trial status of the study related to CNM-Au8 in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CNM-Au8 development?
• What are the key designations that have been granted to CNM-Au8 for Parkinson's disease?
• What is the forecasted market scenario of CNM-Au8 for Parkinson's disease?
• What are the forecasted sales of CNM-Au8 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to CNM-Au8 for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

Table of Contents

1. Report Introduction

2. CNM-Au8 Overview in Parkinson's disease

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and Efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. CNM-Au8 Market Assessment

• 5.1. Market Outlook of CNM-Au8 in Parkinson's disease
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of CNM-Au8 in the 7MM for Parkinson's disease
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of CNM-Au8 in the United States for Parkinson's disease
  • 5.3.2. Market Size of CNM-Au8 in Germany for Parkinson's disease
  • 5.3.3. Market Size of CNM-Au8 in France for Parkinson's disease
  • 5.3.4. Market Size of CNM-Au8 in Italy for Parkinson's disease
  • 5.3.5. Market Size of CNM-Au8 in Spain for Parkinson's disease
  • 5.3.6. Market Size of CNM-Au8 in the United Kingdom for Parkinson's disease
  • 5.3.7. Market Size of CNM-Au8 in Japan for Parkinson's disease

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options